Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALGN's Cash to Debt is ranked higher than
85% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. ALGN: No Debt )
ALGN' s 10-Year Cash to Debt Range
Min: 5.57   Max: No Debt
Current: No Debt

Equity to Asset 0.76
ALGN's Equity to Asset is ranked higher than
79% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ALGN: 0.76 )
ALGN' s 10-Year Equity to Asset Range
Min: -1.2   Max: 0.84
Current: 0.76

-1.2
0.84
Interest Coverage No Debt
ALGN's Interest Coverage is ranked higher than
73% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. ALGN: No Debt )
ALGN' s 10-Year Interest Coverage Range
Min: 22.24   Max: 9999.99
Current: No Debt

22.24
9999.99
F-Score: 6
Z-Score: 13.72
M-Score: -3.03
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 14.27
ALGN's Operating margin (%) is ranked higher than
86% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 6.25 vs. ALGN: 14.27 )
ALGN' s 10-Year Operating margin (%) Range
Min: -3577.86   Max: 26.54
Current: 14.27

-3577.86
26.54
Net-margin (%) 9.74
ALGN's Net-margin (%) is ranked higher than
82% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 4.82 vs. ALGN: 9.74 )
ALGN' s 10-Year Net-margin (%) Range
Min: -3750.61   Max: 26.31
Current: 9.74

-3750.61
26.31
ROE (%) 10.14
ALGN's ROE (%) is ranked higher than
81% of the 365 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. ALGN: 10.14 )
ALGN' s 10-Year ROE (%) Range
Min: -113.17   Max: 36.6
Current: 10.14

-113.17
36.6
ROA (%) 7.73
ALGN's ROA (%) is ranked higher than
85% of the 380 Companies
in the Global Medical Devices industry.

( Industry Median: 3.09 vs. ALGN: 7.73 )
ALGN' s 10-Year ROA (%) Range
Min: -125.77   Max: 28.63
Current: 7.73

-125.77
28.63
ROC (Joel Greenblatt) (%) 124.38
ALGN's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 379 Companies
in the Global Medical Devices industry.

( Industry Median: 12.55 vs. ALGN: 124.38 )
ALGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -443.32   Max: 334.81
Current: 124.38

-443.32
334.81
Revenue Growth (%) 17.20
ALGN's Revenue Growth (%) is ranked higher than
91% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ALGN: 17.20 )
ALGN' s 10-Year Revenue Growth (%) Range
Min: 7.6   Max: 144.4
Current: 17.2

7.6
144.4
EBITDA Growth (%) -3.70
ALGN's EBITDA Growth (%) is ranked higher than
74% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. ALGN: -3.70 )
ALGN' s 10-Year EBITDA Growth (%) Range
Min: -35.2   Max: 44.9
Current: -3.7

-35.2
44.9
EPS Growth (%) -6.40
ALGN's EPS Growth (%) is ranked higher than
68% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. ALGN: -6.40 )
ALGN' s 10-Year EPS Growth (%) Range
Min: -76.1   Max: 289.3
Current: -6.4

-76.1
289.3
» ALGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

ALGN Guru Trades in Q1 2013

Steven Cohen 241,354 sh (+4001.17%)
Ron Baron 29,800 sh (unchged)
Mariko Gordon 83,210 sh (unchged)
RS Investment Management Sold Out
Mario Gabelli 31,000 sh (-3.13%)
John Hussman 597,000 sh (-6.72%)
Pioneer Investments 328,300 sh (-12.08%)
» More
Q2 2013

ALGN Guru Trades in Q2 2013

Jim Simons 28,000 sh (New)
Mario Gabelli 31,000 sh (unchged)
Ron Baron 29,800 sh (unchged)
John Hussman Sold Out
Mariko Gordon 83,088 sh (-0.15%)
Pioneer Investments 296,400 sh (-9.72%)
Steven Cohen 2,477 sh (-98.97%)
» More
Q3 2013

ALGN Guru Trades in Q3 2013

Steven Cohen 5,105 sh (+106.1%)
Jim Simons 28,800 sh (+2.86%)
Ron Baron 29,800 sh (unchged)
Mariko Gordon 82,976 sh (-0.13%)
Mario Gabelli 30,000 sh (-3.23%)
Pioneer Investments 197,426 sh (-33.39%)
» More
Q4 2013

ALGN Guru Trades in Q4 2013

Paul Tudor Jones 23,852 sh (New)
Jim Simons 675,081 sh (+2244.03%)
Steven Cohen 6,322 sh (+23.84%)
Ron Baron 29,800 sh (unchged)
Mariko Gordon Sold Out
Pioneer Investments 115,339 sh (-41.58%)
Mario Gabelli 14,000 sh (-53.33%)
» More
» Details

Insider Trades

Latest Guru Trades with ALGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mariko Gordon 2013-12-31 Sold Out 0.18%$42.52 - $58.59 $ 53.4-1%0
Mario Gabelli 2013-12-31 Reduce -53.33%$42.52 - $58.59 $ 53.4-1%14000
John Hussman 2013-06-30 Sold Out 0.73%$30.13 - $38.16 $ 53.455%0
Ron Baron 2012-12-31 New Buy0.01%$25.39 - $38.9 $ 53.485%29800
Mario Gabelli 2012-09-30 Reduce -31.91%$29.25 - $39.19 $ 53.454%32000
John Hussman 2012-06-30 Reduce -39.92%0.27%$26.67 - $34.35 $ 53.475%751000
George Soros 2012-06-30 Sold Out 0.03%$26.67 - $34.35 $ 53.475%0
Joel Greenblatt 2012-03-31 Sold Out 0.1%$22.67 - $28.24 $ 53.4123%0
George Soros 2012-03-31 New Buy0.03%$22.67 - $28.24 $ 53.4123%75000
Joel Greenblatt 2011-09-30 Add 117.09%0.05%$14.96 - $24.02 $ 53.4174%39882
Joel Greenblatt 2011-06-30 Reduce -21.09%0.03%$20.7 - $24.99 $ 53.4131%18371
George Soros 2011-06-30 Sold Out $20.7 - $24.99 $ 53.4131%0
Joel Greenblatt 2011-03-31 Add 52.1%0.05%$19.5 - $22.05 $ 53.4158%23280
Mario Gabelli 2011-03-31 Reduce -43.22%0.01%$19.5 - $22.05 $ 53.4158%67000
George Soros 2011-03-31 New Buy$19.5 - $22.05 $ 53.4158%14300
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 69.10
ALGN's P/E(ttm) is ranked lower than
60% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. ALGN: 69.10 )
ALGN' s 10-Year P/E(ttm) Range
Min: 5.22   Max: 489.21
Current: 69.1

5.22
489.21
P/B 6.60
ALGN's P/B is ranked lower than
69% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ALGN: 6.60 )
ALGN' s 10-Year P/B Range
Min: 1.86   Max: 19.24
Current: 6.6

1.86
19.24
P/S 6.70
ALGN's P/S is ranked lower than
73% of the 372 Companies
in the Global Medical Devices industry.

( Industry Median: 2.74 vs. ALGN: 6.70 )
ALGN' s 10-Year P/S Range
Min: 1.31   Max: 9.76
Current: 6.7

1.31
9.76
PFCF 26.60
ALGN's PFCF is ranked higher than
64% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. ALGN: 26.60 )
ALGN' s 10-Year PFCF Range
Min: 11.21   Max: 2846
Current: 26.6

11.21
2846
EV-to-EBIT 40.00
ALGN's EV-to-EBIT is ranked lower than
61% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 20.91 vs. ALGN: 40.00 )
ALGN' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 287.7
Current: 40

10.3
287.7
Shiller P/E 71.60
ALGN's Shiller P/E is ranked lower than
64% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 27.00 vs. ALGN: 71.60 )
ALGN' s 10-Year Shiller P/E Range
Min: 30.52   Max: 136.15
Current: 71.6

30.52
136.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.00
ALGN's Price/Net Cash is ranked lower than
67% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. ALGN: 25.00 )
ALGN' s 10-Year Price/Net Cash Range
Min: 5.1   Max: 117.93
Current: 25

5.1
117.93
Price/Net Current Asset Value 16.30
ALGN's Price/Net Current Asset Value is ranked lower than
64% of the 174 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. ALGN: 16.30 )
ALGN' s 10-Year Price/Net Current Asset Value Range
Min: 4.19   Max: 38.81
Current: 16.3

4.19
38.81
Price/Tangible Book 7.80
ALGN's Price/Tangible Book is ranked lower than
70% of the 328 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ALGN: 7.80 )
ALGN' s 10-Year Price/Tangible Book Range
Min: 2.06   Max: 15.29
Current: 7.8

2.06
15.29
Price/DCF (Projected) 2.60
ALGN's Price/DCF (Projected) is ranked lower than
53% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. ALGN: 2.60 )
ALGN' s 10-Year Price/DCF (Projected) Range
Min: 1.73   Max: 14.76
Current: 2.6

1.73
14.76
Price/Median PS Value 1.60
ALGN's Price/Median PS Value is ranked lower than
61% of the 338 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. ALGN: 1.60 )
ALGN' s 10-Year Price/Median PS Value Range
Min: 0.46   Max: 1.91
Current: 1.6

0.46
1.91
Price/Graham Number 4.80
ALGN's Price/Graham Number is ranked lower than
72% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ALGN: 4.80 )
ALGN' s 10-Year Price/Graham Number Range
Min: 0.95   Max: 7.44
Current: 4.8

0.95
7.44
Earnings Yield (Greenblatt) 2.50
ALGN's Earnings Yield (Greenblatt) is ranked lower than
53% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. ALGN: 2.50 )
ALGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 9.7
Current: 2.5

0.3
9.7
Forward Rate of Return (Yacktman) 1.77
ALGN's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ALGN: 1.77 )
ALGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -54.9   Max: 3.7
Current: 1.77

-54.9
3.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AFW.Germany
Align Technology, Inc. was incorporated in Delaware in April 1997. The Company designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The Company has two operating segments namely Clear Aligner, known as the Invisalign system; and Scanners and CAD/CAM Services, known as iTero and iOC intra-oral scanners and OrthoCAD services. The Company distributes the vast majority of its products directly to its customers: orthodontists and general practitioner dentists, or GPs, as well as to restorative dentists, including prosthodontists, periodontists, and oral surgeons. The Company received the United States Food and Drug Administration ("FDA") clearance to market the Invisalign system in 1998. The Invisalign system is regulated by the FDA as a Class II medical device. In order to provide Invisalign treatment to their patients, orthodontists and GPs must initially complete an Invisalign training course. The Invisalign system is sold in North America, Europe, Asia Pacific, Latin America and Japan. The Company uses a distributor model for the sale of its products in non-core country markets in the Asia Pacific, Europe, the Middle East and Africa (EMEA), and Latin America regions. Malocclusion and Traditional Orthodontic Treatment is one of the most prevalent clinical dental conditions, affecting nearly a billion people, or approximately 50 to 75% of the population of major developed countries. Approximately 6.8 million people annually elect treatment by orthodontists worldwide, of which approximately 2.6 million have mild to moderate malocclusion and are applicable to Invisalign treatment-it served market. The Invisalign system is a proprietary method for treating malocclusion based on a series of doctor-prescribed, custom manufactured, clear plastic removable orthodontic aligners. The Invisalign system offers a range of treatment options, specialized services, and proprietary software for treatment visualization. The Company markets Invisalign by communicating the benefits of the Invisalign system to dental professionals through its training programs, mail campaigns, trade shows, trade journals and print media, and to consumers through advertising, digital media, event marketing and social networking activities. Based on its experience with advertising and commercial sales, the Company believes that making consumers aware of Invisalign as a new treatment alternative generates significant demand for Invisalign. It competes for the attention of dental professionals with manufacturers of traditional orthodontic appliances (or wires and brackets), which include 3M's Unitek, Danaher Corporation's Sybron Dental Specialties, and Dentsply International, Inc.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide